Published in J Clin Oncol on July 15, 2003
Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut (2005) 3.32
Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology (2008) 3.04
Carcinoid tumors. Oncologist (2008) 2.86
Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut (2011) 2.14
ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology (2012) 1.86
Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors. World J Gastroenterol (2010) 1.23
Cancer treatment using peptides: current therapies and future prospects. J Amino Acids (2012) 1.23
Multimodal management of neuroendocrine liver metastases. HPB (Oxford) (2010) 1.21
Antitumor effects of somatostatin analogs in neuroendocrine tumors. Oncologist (2012) 1.17
Alkaline phosphatase predicts survival in patients with metastatic neuroendocrine tumors. Dig Dis Sci (2006) 1.13
A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors. Cancer Chemother Pharmacol (2010) 1.11
Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study. BMC Cancer (2013) 1.09
Long-term results of surgery for small intestinal neuroendocrine tumors at a tertiary referral center. World J Surg (2012) 1.07
Biological characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors: tumor grade and metastatic site are important for treatment strategy. BMC Cancer (2010) 1.01
Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives. J Exp Clin Cancer Res (2010) 1.01
Treatment of advanced disease in patients with well-differentiated neuroendocrine tumors. Nat Clin Pract Oncol (2009) 0.96
Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte oncology network. BMC Cancer (2009) 0.96
Liver metastases of neuroendocrine tumours; early reduction of tumour load to improve life expectancy. World J Surg Oncol (2006) 0.94
A multimodal approach to the management of neuroendocrine tumour liver metastases. Int J Hepatol (2012) 0.94
A new era for the systemic therapy of neuroendocrine tumors. Oncologist (2012) 0.89
Recent trends in the treatment of well-differentiated endocrine carcinoma of the small bowel. World J Gastroenterol (2010) 0.89
Systemic chemo-immunotherapy for advanced-stage hepatocellular carcinoma. World J Gastroenterol (2005) 0.87
Correlation between expression of gastrin, somatostatin and cell apoptosis regulation gene bcl-2/bax in large intestine carcinoma. World J Gastroenterol (2005) 0.87
Is surgery indicated for patients with symptomatic nonfunctioning pancreatic neuroendocrine tumor and unresectable hepatic metastases? World J Surg (2007) 0.87
Effect of Peptide Receptor Radionuclide Therapy on Somatostatin Receptor Status and Glucose Metabolism in Neuroendocrine Tumors: Intraindividual Comparison of Ga-68 DOTANOC PET/CT and F-18 FDG PET/CT. Int J Mol Imaging (2011) 0.85
Care for patients with multiple endocrine neoplasia type 1: the current evidence base. Fam Cancer (2011) 0.84
Multidisciplinary management of advanced lung neuroendocrine tumors. J Thorac Dis (2015) 0.83
Treatment of gastroenteropancreatic neuroendocrine tumors. Virchows Arch (2007) 0.83
Hepatic resection for metastatic gastrointestinal and pancreatic neuroendocrine tumours: outcome and prognostic predictors. HPB (Oxford) (2007) 0.82
The expanding role of somatostatin analogs in the management of neuroendocrine tumors. Gastrointest Cancer Res (2012) 0.82
Liver-specific therapies for metastases of neuroendocrine pancreatic tumors. World J Hepatol (2010) 0.81
Evaluating the activity of temsirolimus in neuroendocrine cancer. Br J Cancer (2006) 0.81
Combination of Capecitabine and Oxaliplatin is an Effective Treatment Option for Advanced Neuroendocrine Tumors. Rare Tumors (2013) 0.80
Alteration of somatostatin receptor subtype 2 gene expression in pancreatic tumor angiogenesis. World J Gastroenterol (2004) 0.80
Correlation between the expressions of gastrin, somatostatin and cyclin and cyclin-depend kinase in colorectal cancer. World J Gastroenterol (2005) 0.80
Chemo-hormone therapy of non-well-differentiated endocrine tumours from different anatomic sites with cisplatinum, etoposide and slow release lanreotide formulation. Br J Cancer (2007) 0.80
Current understanding and approach to well differentiated lung neuroendocrine tumors: an update on classification and management. Ther Adv Med Oncol (2016) 0.79
Safety and efficacy of sunitinib in patients with unresectable pancreatic neuroendocrine tumors. Clin Med Insights Oncol (2012) 0.79
Role of surgery and transplantation in the treatment of hepatic metastases from neuroendocrine tumor. World J Gastroenterol (2014) 0.78
Advances in the treatment of gastroenteropancreatic neuroendocrine tumors. Clin Exp Gastroenterol (2010) 0.78
Well-differentiated neuroendocrine tumors: a review covering basic principles to loco-regional and targeted therapies. Oncogene (2010) 0.78
Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors. Endocr Relat Cancer (2014) 0.78
Medical treatment of gastroenteropancreatic neuroendocrine tumors. Cancers (Basel) (2012) 0.78
Systemic therapy for advanced pancreatic neuroendocrine tumors. Semin Oncol (2013) 0.78
GIPR expression in gastric and duodenal neuroendocrine tumors. J Surg Res (2014) 0.77
Targeted therapy in advanced well-differentiated neuroendocrine tumors. Oncologist (2011) 0.77
Refractory carcinoid syndrome: a review of treatment options. Ther Adv Med Oncol (2016) 0.76
Medical treatment of gastrinomas. Wien Klin Wochenschr (2007) 0.76
Beyond peptides and mAbs--current status and future perspectives for biotherapeutics with novel constructs. J Clin Pharmacol (2015) 0.76
Liver resection for liver metastases from nondigestive endocrine cancer: extrahepatic disease burden defines outcome. Surgery (2012) 0.76
Nonfunctional Pancreatic Neuroendocrine Tumors: Advances in Diagnosis, Management, and Controversies. Int Surg (2015) 0.76
An Interesting Case of Recurrent Small Bowel Obstruction. Case Rep Gastroenterol (2009) 0.75
Update on management of midgut neuroendocrine tumors. Int J Endocr Oncol (2016) 0.75
Is lanreotide and/or interferon alfa an adequate therapy for neuroendocrine tumors? J Clin Oncol (2004) 0.75
Gastroenteropancreatic neuroendocrine tumors: recommendations of Turkish multidisciplinary neuroendocrine tumor study group on diagnosis, treatment and follow-up. Arch Med Sci (2017) 0.75
Nonfunctional neuroendocrine tumor of the pancreas: Case report and review of the literature. Int J Surg Case Rep (2012) 0.75
Everolimus in the management of metastatic neuroendocrine tumours. Therap Adv Gastroenterol (2016) 0.75
Predictive factors of antiproliferative activity of octreotide LAR as first-line therapy for advanced neuroendocrine tumours. Br J Cancer (2016) 0.75
Association Between Somatostatin Receptor Expression and Clinical Outcomes in Neuroendocrine Tumors. Pancreas (2016) 0.75
The Treatment of Liver Metastases in Patients with Neuroendocrine Tumors in 2012. ISRN Hepatol (2013) 0.75
Comprehensive treatment of a functional pancreatic neuroendocrine tumor with multifocal liver metastases. Chin J Cancer Res (2014) 0.75
Summary of emerging personalized medicine in neuroendocrine tumors: are we on track? J Gastrointest Oncol (2016) 0.75
New therapeutic approaches to metastatic gastroenteropancreatic neuroendocrine tumors: A glimpse into the future. World J Gastrointest Oncol (2017) 0.75
Management of controversial gastroenteropancreatic neuroendocrine tumour clinical situations with somatostatin analogues: results of a Delphi questionnaire panel from the NETPraxis program. BMC Cancer (2016) 0.75
Management of the hormonal syndrome of neuroendocrine tumors. Arch Med Sci (2016) 0.75
Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors. J Clin Oncol (2004) 0.75
Antiproliferative effect of somatostatin analogs in advanced gastro-entero-pancreatic neuroendocrine tumors: a systematic review and meta-analysis. Oncotarget (2017) 0.75
The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors. Pancreas (2017) 0.75
Interferon-alpha Treatment for Disease Control in Metastatic Pheochromocytoma/Paraganglioma Patients. Horm Cancer (2017) 0.75
Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med (2011) 11.93
Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol (2009) 9.27
A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med (2013) 6.09
Acupuncture and knee osteoarthritis: a three-armed randomized trial. Ann Intern Med (2006) 4.42
Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology (2003) 3.93
Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology (2004) 3.70
Longevity of materials for pit and fissure sealing--results from a meta-analysis. Dent Mater (2011) 3.56
Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol (2009) 3.18
Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology (2010) 3.02
ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology (2012) 3.00
Acute appendicitis is characterised by local invasion with Fusobacterium nucleatum/necrophorum. Gut (2009) 2.98
Identification of a common gene expression signature in dilated cardiomyopathy across independent microarray studies. J Am Coll Cardiol (2006) 2.73
Magnetic resonance colonography for the detection of colorectal neoplasia in asymptomatic adults. Gastroenterology (2013) 2.71
Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology (2006) 2.68
Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncol (2010) 2.66
Multiple levels of regulation of the interleukin-6 system in stroke. Stroke (2003) 2.61
Chymotrypsin C (CTRC) variants that diminish activity or secretion are associated with chronic pancreatitis. Nat Genet (2007) 2.48
An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. Blood (2008) 2.46
Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours. Eur J Nucl Med Mol Imaging (2004) 2.45
GlobalANCOVA: exploration and assessment of gene group effects. Bioinformatics (2007) 2.24
Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst (2003) 2.19
Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol (2010) 2.18
Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer (2008) 2.16
Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide. Neuroendocrinology (2004) 2.16
Activated signal transducer and activator of transcription 3 (STAT3) supports the malignant phenotype of human pancreatic cancer. Gastroenterology (2003) 2.16
Successful recanalization of a completely obliterated esophageal stricture by using an endoscopic rendezvous maneuver. Gastrointest Endosc (2005) 2.12
Variants in CPA1 are strongly associated with early onset chronic pancreatitis. Nat Genet (2013) 2.10
Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer (2008) 2.08
Inhalation treatment with glutathione in patients with cystic fibrosis. A randomized clinical trial. Am J Respir Crit Care Med (2013) 2.07
Course of platelet activation markers after ischemic stroke. Stroke (2002) 2.05
Factors affecting and affected by user acceptance of computer-based nursing documentation: results of a two-year study. J Am Med Inform Assoc (2003) 2.05
An adherent Gardnerella vaginalis biofilm persists on the vaginal epithelium after standard therapy with oral metronidazole. Am J Obstet Gynecol (2007) 2.04
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology (2009) 1.92
Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon Alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma. J Clin Oncol (2012) 1.90
A degradation-sensitive anionic trypsinogen (PRSS2) variant protects against chronic pancreatitis. Nat Genet (2006) 1.90
Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology (2003) 1.86
Comparative study of the intestinal mucus barrier in normal and inflamed colon. Gut (2006) 1.81
Narrow-band versus white-light high definition television endoscopic imaging for screening colonoscopy: a prospective randomized trial. Gastroenterology (2008) 1.76
Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study. Endocr Relat Cancer (2012) 1.76
Multiple testing on the directed acyclic graph of gene ontology. Bioinformatics (2008) 1.69
A prospective randomized study to assess the efficacy of a surgical sealant to treat air leaks in lung surgery. Eur J Cardiothorac Surg (2009) 1.68
Strong gametocytocidal effect of methylene blue-based combination therapy against falciparum malaria: a randomised controlled trial. PLoS One (2009) 1.68
Consensus guidelines for the management of patients with digestive neuroendocrine tumors--well-differentiated jejunal-ileal tumor/carcinoma. Neuroendocrinology (2007) 1.67
Cost comparison of 111In-DTPA-octreotide scintigraphy and 68Ga-DOTATOC PET/CT for staging enteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging (2011) 1.59
Enhanced innate immune responsiveness and intolerance to intestinal endotoxins in human biliary epithelial cells contributes to chronic cholangitis. Liver Int (2011) 1.57
Glucocorticoids regulate barrier function and claudin expression in intestinal epithelial cells via MKP-1. Am J Physiol Gastrointest Liver Physiol (2013) 1.56
Oxidative stress regulates vascular endothelial growth factor-A gene transcription through Sp1- and Sp3-dependent activation of two proximal GC-rich promoter elements. J Biol Chem (2002) 1.56
The majority of intestinal IgA+ and IgG+ plasmablasts in the human gut are antigen-specific. J Clin Invest (2011) 1.53
Outcome and toxicity of salvage therapy with 177Lu-octreotate in patients with metastatic gastroenteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging (2013) 1.52
Proteomic analysis of the inflamed intestinal mucosa reveals distinctive immune response profiles in Crohn's disease and ulcerative colitis. J Immunol (2007) 1.51
Data quality of the German screening colonoscopy registry. Endoscopy (2013) 1.48
A compendium to ensure computational reproducibility in high-dimensional classification tasks. Stat Appl Genet Mol Biol (2004) 1.48
Transforming growth factor beta 1 stimulates vascular endothelial growth factor gene transcription in human cholangiocellular carcinoma cells. Cancer Res (2003) 1.48
Long-term prophylactic treatment of attacks of vertigo in Menière's disease--comparison of a high with a low dosage of betahistine in an open trial. Acta Otolaryngol (2008) 1.48
Bombesin, but not amylin, blocks the orexigenic effect of peripheral ghrelin. Am J Physiol Regul Integr Comp Physiol (2006) 1.47
The cell-cell adhesion molecule EpCAM interacts directly with the tight junction protein claudin-7. Exp Cell Res (2005) 1.47
Cardiac surgery for carcinoid heart disease in 12 cases. Gen Thorac Cardiovasc Surg (2011) 1.46
Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome. Cancer (2011) 1.46
Autoregulation of Th1-mediated inflammation by twist1. J Exp Med (2008) 1.43
Antireflux 'barriers': problems with patient recruitment for a new endoscopic antireflux procedure. Eur J Gastroenterol Hepatol (2009) 1.43
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biochemical markers. Neuroendocrinology (2009) 1.42
Quantification of melanoma micrometastases in sentinel lymph nodes using real-time RT-PCR. J Invest Dermatol (2005) 1.39
Omega-3 fatty acids and their lipid mediators: towards an understanding of resolvin and protectin formation. Prostaglandins Other Lipid Mediat (2012) 1.38
Methylene blue for malaria in Africa: results from a dose-finding study in combination with chloroquine. Malar J (2006) 1.37
Galectin-1 interacts with the {alpha}5{beta}1 fibronectin receptor to restrict carcinoma cell growth via induction of p21 and p27. J Biol Chem (2005) 1.37
Gastric hyperplasia in mice with targeted disruption of the carbonic anhydrase gene Car9. Gastroenterology (2002) 1.35
Neuroendocrine neoplasms of the gut and pancreas: new insights. Nat Rev Endocrinol (2011) 1.35
CFH, C3 and ARMS2 are significant risk loci for susceptibility but not for disease progression of geographic atrophy due to AMD. PLoS One (2009) 1.34
Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression. Cancer Res (2008) 1.34
Safety of the methylene blue plus chloroquine combination in the treatment of uncomplicated falciparum malaria in young children of Burkina Faso [ISRCTN27290841]. Malar J (2005) 1.28
A Toll-like receptor 7 single nucleotide polymorphism protects from advanced inflammation and fibrosis in male patients with chronic HCV-infection. J Hepatol (2007) 1.27
Hypoxia-inducible factor 1alpha determines gastric cancer chemosensitivity via modulation of p53 and NF-kappaB. PLoS One (2010) 1.27
Human galectin-2: novel inducer of T cell apoptosis with distinct profile of caspase activation. J Immunol (2004) 1.23
Safety of the combination of chloroquine and methylene blue in healthy adult men with G6PD deficiency from rural Burkina Faso. Trop Med Int Health (2005) 1.23
Safety and efficacy of methylene blue combined with artesunate or amodiaquine for uncomplicated falciparum malaria: a randomized controlled trial from Burkina Faso. PLoS One (2008) 1.22
Detection of miR-34a promoter methylation in combination with elevated expression of c-Met and β-catenin predicts distant metastasis of colon cancer. Clin Cancer Res (2012) 1.21
Well-differentiated pancreatic tumor/carcinoma: insulinoma. Neuroendocrinology (2007) 1.21
Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease--a long-term follow-up. Am J Gastroenterol (2006) 1.19
Hypoxia-inducible factor 1alpha mediates anoikis resistance via suppression of alpha5 integrin. Cancer Res (2008) 1.19
Can evaluation studies benefit from triangulation? A case study. Int J Med Inform (2003) 1.18
Concordance of disease progression in bilateral geographic atrophy due to AMD. Invest Ophthalmol Vis Sci (2009) 1.17
EUS-guided FNA of solid pancreatic masses: high yield of 2 passes with combined histologic-cytologic analysis. Gastrointest Endosc (2009) 1.17
Diagnosis of red cell G6PD deficiency in rural Burkina Faso: comparison of a rapid fluorescent enzyme test on filter paper with polymerase chain reaction based genotyping. Br J Haematol (2005) 1.17
Step-wedge cluster-randomised community-based trials: an application to the study of the impact of community health insurance. Health Res Policy Syst (2008) 1.15
High-dimensional Cox models: the choice of penalty as part of the model building process. Biom J (2010) 1.15
Escherichia coli Nissle 1917 distinctively modulates T-cell cycling and expansion via toll-like receptor 2 signaling. Infect Immun (2005) 1.15
Sample size determinations in original research protocols for randomised clinical trials submitted to UK research ethics committees: review. BMJ (2013) 1.15
Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative study. J Clin Oncol (2013) 1.15
Desacyl ghrelin inhibits the orexigenic effect of peripherally injected ghrelin in rats. Peptides (2008) 1.14
Tight junction-related structures in the absence of a lumen: occludin, claudins and tight junction plaque proteins in densely packed cell formations of stratified epithelia and squamous cell carcinomas. Eur J Cell Biol (2003) 1.13
Alternative regression models to assess increase in childhood BMI. BMC Med Res Methodol (2008) 1.13
A subgroup of age-related macular degeneration is associated with mono-allelic sequence variants in the ABCA4 gene. Invest Ophthalmol Vis Sci (2012) 1.10
Differential priming of CD8 and CD4 T-cells in animal models of autoimmune hepatitis and cholangitis. Hepatology (2007) 1.10
Survival and clinical outcome of patients with neuroendocrine tumors of the gastroenteropancreatic tract in a german referral center. Ann N Y Acad Sci (2004) 1.09